These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27681701)

  • 1. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.
    Kachru N; Sura S; Chatterjee S; Aparasu RR
    Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
    Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
    BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
    Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
    Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported reasons for discontinuing overactive bladder medication.
    Benner JS; Nichol MB; Rovner ES; Jumadilova Z; Alvir J; Hussein M; Fanning K; Trocio JN; Brubaker L
    BJU Int; 2010 May; 105(9):1276-82. PubMed ID: 19912188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of discontinuing overactive bladder medications.
    Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
    BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder.
    Suehs BT; Davis C; Franks B; Yuran TE; Ng D; Bradt J; Knispel J; Vassilakis M; Berner T
    J Am Geriatr Soc; 2016 Apr; 64(4):779-87. PubMed ID: 27059714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients.
    Yoshida M; Kato D; Nishimura T; Van Schyndle J; Uno S; Kimura T
    Int J Urol; 2018 Oct; 25(10):855-862. PubMed ID: 30069973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
    Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
    Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study.
    Arana A; Margulis AV; McQuay LJ; Ziemiecki R; Bartsch JL; Rothman KJ; Franks B; D'Silva M; Appenteng K; Varas-Lorenzo C; Perez-Gutthann S
    Pharmacotherapy; 2018 Jun; 38(6):628-637. PubMed ID: 29723926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the Pharmacological Management of Nursing Home Residents with Overactive Bladder or Urinary Incontinence.
    Zarowitz BJ; Allen C; O'Shea T; Tangalos EG; Berner T; Ouslander JG
    J Am Geriatr Soc; 2015 Nov; 63(11):2298-307. PubMed ID: 26503458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
    Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
    Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
    Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder.
    Suehs BT; Davis C; Ng DB; Gooch K
    Drugs Aging; 2017 Jul; 34(7):535-543. PubMed ID: 28540648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
    Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK
    Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
    Margulis AV; Linder M; Arana A; Pottegård A; Berglind IA; Bui CL; Kristiansen NS; Bahmanyar S; McQuay LJ; Atsma WJ; Appenteng K; D'Silva M; Perez-Gutthann S; Hallas J
    PLoS One; 2018; 13(9):e0204456. PubMed ID: 30260993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.